Bristol-Myers Squibb Eyes A Jewel To Add To Its String Of Pearls
This article was originally published in The Pink Sheet Daily
Executive Summary
$4.5 billion cash takeover of ImClone would give BMS 100 percent of North American Erbitux sales that totaled $700 million in the first half.
You may also be interested in...
Bristol Sweetens ImClone Bid A Bit, Plans To Ask Stockholders To Replace Board
BMS ups ante by $2 per share, for a total $4.7 billion cash offer.
Bristol Sweetens ImClone Bid A Bit, Plans To Ask Stockholders To Replace Board
BMS ups ante by $2 per share, for a total $4.7 billion cash offer.
Survey: Oncologists Show Support For Erbitux Uptake Based On KRAS Test
Approach could encourage front-line Erbitux use in some colorectal patients, Rodman & Renshaw finds after oncologist survey.